Ayala Pharmaceuticals (NASDAQ:AYLA) issued its earnings results on Friday. The company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.03), MarketWatch Earnings reports. Ayala Pharmaceuticals had a negative return on equity of 625.24% and a negative net margin of 850.81%.
AYLA stock traded up $0.20 during trading hours on Friday, hitting $10.00. 25,273 shares of the stock traded hands, compared to its average volume of 29,345. The stock has a 50-day simple moving average of $10.54 and a 200 day simple moving average of $12.41. Ayala Pharmaceuticals has a one year low of $8.62 and a one year high of $28.68.
AYLA has been the subject of several recent analyst reports. Noble Financial reissued a “buy” rating on shares of Ayala Pharmaceuticals in a research note on Monday, January 25th. Zacks Investment Research cut Ayala Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Ayala Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $24.20.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
Recommended Story: What is a Candlestick Chart?
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.